Sarepta selloff yesterday a buying opportunity, says Mizuho

Mizuho analyst Uy Ear spoke to Sarepta Therapeutics about the selloff in the shares yesterday and was told the price decline is “nothing fundamental,” suggesting to the firm that it is not EMBARK-related. Sarepta continues to expect the readout for the confirmatory Phase 3 EMBARK trial in Q4, the analyst tells investors in a research note. Mizuho says investor feedback suggests the price decline may be driven by the unwinding of a poorly performing hedge fund. It sees the selloff as a buying opportunity and keeps a Buy rating on the shares with a $160 price target.